Vericel closed its underwritten public offering of 5,750,000 shares of is common stock for $13/share, for gross proceeds of ~US $74.8MM.
As announced, funds will support general corporate purposes and potential expansion by in-licensing or acquiring complementary product candidates, technologies, etc., though the company has no current commitments or obligations to do so.
Vericel has developed the MACI autologous cultured chondrocyte product for cartilage repair.
Vericel closed its underwritten public offering of 5,750,000 shares of is common stock for $13/share, for gross proceeds of ~US $74.8MM.
As announced, funds will support general corporate purposes and potential expansion by in-licensing or acquiring complementary product candidates, technologies, etc., though the company has no current...
Vericel closed its underwritten public offering of 5,750,000 shares of is common stock for $13/share, for gross proceeds of ~US $74.8MM.
As announced, funds will support general corporate purposes and potential expansion by in-licensing or acquiring complementary product candidates, technologies, etc., though the company has no current commitments or obligations to do so.
Vericel has developed the MACI autologous cultured chondrocyte product for cartilage repair.
Copy to clipboard 
